TCR Optimization via Reinforcement Learning Mutation Policies
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current computational methods for optimizing T-cell receptors (TCRs) for immunotherapy are time-consuming and inefficient, as they fail to generate high-affinity TCRs tailored to recognize specific peptides, and do not validate the generated sequences effectively.
Innovation Solution
A deep reinforcement learning framework, TCRPPO, is developed to optimize TCRs using a mutation policy, incorporating a reward function that measures both the validity and recognition probability of mutated sequences, leveraging a TCR auto-encoder and peptide-TCR binding predictors to generate qualified TCRs with high binding scores.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If current computational methods are used to optimize TCRs, then the process can be completed, but it is time-consuming and inefficient with low success rate in generating high-affinity TCRs
Solution Approach 1:
The patent implements feedback mechanisms through reward functions that evaluate generated TCR sequences using binding affinity predictors and validity checkers. The reinforcement learning agent continuously receives feedback on the quality of generated TCRs and adjusts its generation strategy accordingly, improving both speed and success rate through iterative optimization.
Solution Approach 2:
The patent replaces traditional brute-force computational methods with a reinforcement learning-based generative model. This substitution of the computational approach dramatically reduces optimization time while improving the reliability of generating high-affinity TCRs through learned patterns from training data.
2Manufacturing precision
If traditional TCR optimization methods are used, then computation can be performed, but they fail to effectively validate the generated sequences
Solution Approach 1:
The patent performs preliminary validation by integrating binding affinity predictors and TCR validity checkers into the generation process itself. Sequences are validated during generation rather than after, ensuring high validity while managing complexity through integrated rather than separate validation steps.
Solution Approach 2:
The patent introduces intermediary validation components (binding affinity predictors and validity checkers) that mediate between the generative model and the final TCR output. These intermediaries provide structured validation feedback without requiring the entire system to become overly complex.
3Manufacturing precision
If reinforcement learning with mutation policies is implemented, then TCRs with maximum binding scores can be generated, but the system complexity increases
Solution Approach 1:
The patent segments the complex reinforcement learning framework into distinct functional modules: a policy network for mutation decisions, a value network for evaluation, binding affinity predictors for scoring, and validity checkers for verification. This segmentation manages complexity by organizing the system into independent, manageable components with clear interfaces.
Data Source
AI summary
A method for implementing deep reinforcement learning with T-cell receptor (TCR) mutation policies to generate binding TCRs recognizing target peptides for immunotherapy is presented. The method includes extracting peptides to identify a virus or tumor cells, collecting a library of TCRs from target patients, predicting, by a deep neural network, interaction scores between the extracted peptides and the TCRs from the target patients, developing a deep reinforcement learning (DRL) framework with TCR mutation policies to generate TCRs with maximum binding scores, defining reward functions based on a reconstruction-based score and a density estimation-based score, randomly sampling batches of TCRs and following a policy network to mutate the TCRs, outputting mutated TCRs, and ranking the outputted TCRs to utilize top-ranked TCR candidates to target the virus or the tumor cells for immunotherapy.